GRI Bio Inc GRI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.17
- Day Range
- $2.05–2.33
- 52-Week Range
- $0.19–80.36
- Bid/Ask
- $2.23 / $2.33
- Shares Outstanding
- 1.77M
- Market Cap
- $4.11M
- Volume/Avg
- 650,224 / 90,695
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
- Website
- https://www.gribio.com
Valuation
|
Metric
|
GRI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.34 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
GRI
Financial Strength
|
Metric
|
GRI
|
|---|---|
Quick Ratio | 13.91 |
Current Ratio | 14.21 |
Interest Coverage | — |
Quick Ratio
GRI
Profitability
|
Metric
|
GRI
|
|---|---|
Return on Assets (Normalized) | −149.32% |
Return on Equity (Normalized) | −223.29% |
Return on Invested Capital (Normalized) | −219.77% |
Return on Assets
GRI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Affymax Inc
AFFY
| — | Xpr | — | |||
| Athersys Inc
ATHXQ
| — | Hwj | — | |||
| Vertex Pharmaceuticals Inc
VRTX
| Pmhfyxtpx | Rpdbb | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mkwwcclbw | Hsnxp | $64B | |||
| UCB SA
UCBJF
| — | Vhnw | $61B | |||
| UCB SA ADR
UCBJY
| — | Tmz | $61B | |||
| argenx SE
ARGNF
| — | Tss | $56B | |||
| argenx SE ADR
ARGX
| Lvggqymj | Hhzp | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Gxwfmwksl | Qbrfq | $38B | |||
| CSL Ltd
CMXHF
| — | Vtrgpkq | $36B |
United States